Journal article
18F-flumazenil: A g-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy
L Vivash, MC Gregoire, EW Lau, RE Ware, D Binns, P Roselt, V Bouilleret, DE Myers, MJ Cook, RJ Hicks, TJ O'Brien
Journal of Nuclear Medicine | Published : 2013
Abstract
Studies report that 11C-flumazenil (FMZ) PET more specifically localizes the epileptogenic zone in patients with medically refractory focal epilepsy than 18F-FDG PET. However, practical aspects of 11C use limit clinical application. We report a phase I/IIa study assessing the clinical use of 18F-FMZ PET for the localization of the epileptogenic zone in patients with drug-resistant temporal lobe epilepsy (TLE). Receptor binding was quantified using kinetic modeling that did not require arterial sampling. Methods: Dynamic 18F-FMZ PET and static interictal 18F-FDG PET scans were compared in healthy controls (n = 17 for 18F-FMZ and n = 20 for 18F-FDG) and TLE patients with mesial temporal sclero..
View full abstractGrants
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was funded by the Cooperative Research Centre for Biomedical Imaging Development Ltd. (CRCBID), Bundoora, Victoria, Australia, established and supported under the Australian Government's Cooperative Research Centers program. Core academic partners of the CRC for Biomedical Imaging Development are the Australian Nuclear Science and Technology Organization (ANSTO), Menai, NSW; the Garvan Institute of Medical Research, Darlinghurst, NSW; Monash University, Clayton, VIC; and the Peter MacCallum Cancer Centre, Melbourne, VIC, all in Australia. Core commercial partners are Berthold Australia Pty Ltd., Bundoora, VIC; Cyclotek (Aust) Pty Ltd., Bundoora, VIC, Australia; and GE Healthcare Pty Ltd., Rydalmere, NSW, Australia. No other potential conflict of interest relevant to this article was reported.